<DOC>
	<DOCNO>NCT00203996</DOCNO>
	<brief_summary>Polycystic ovary syndrome ( PCOS ) affect 5-10 % woman United States . Its onset usually time puberty manifestation menstrual irregularity , hirsutism , obesity . Women PCOS suffer early stage adulthood component metabolic syndrome , syndrome typically peak mid-life subject population . Women PCOS insulin resistant weight-matched control woman exceptionally high rate early-onset impaired glucose tolerance type 2 diabetes , well substantially elevate risk hypertension , dyslipidemia , coronary , vascular disease . While recent evidence indicate prevalence sleep-disordered breathing ( SDB ) 30-40 fold high PCOS weight-matched control woman , possible role SDB cause increase metabolic cardiovascular risk PCOS evaluate . The overall objective propose study analyze direction causality sleep disturbance marker metabolic syndrome PCOS .</brief_summary>
	<brief_title>Polycystic Ovary Syndrome ( PCOS ) Sleep Apnea</brief_title>
	<detailed_description>Polycystic ovary syndrome ( PCOS ) affect 5-10 % woman may view combination hyperandrogenism classical feature metabolic syndrome young woman . PCOS present unique opportunity dissect relationship metabolic cardiovascular risk sleep disorder breathing ( SDB ) population intrinsic effect age yet develop . Because relationship obstructive sleep apnea , insulin resistance elevate testosterone level also observe men woman without PCOS , insight gain study PCOS broad implication . The Specific Aims present application : Specific Aim 1 : test hypothesis sleep disturbance cause hyperandrogenemia hyperinsulinemia characterize PCOS . Following detailed baseline evaluation sleep , hormonal , metabolic cardiovascular parameter , woman PCOS randomize 8-week treatment phase pioglitazone depot leuprolide plus estrogen/progestin replacement placebo . Pioglitazone reduce insulin level , consequently androgen level , PCOS . We compare effect androgen reduction alone ( depot leuprolide plus estrogen/progestin ) insulin plus androgen reduction achieve pioglitazone . Primary comparison change sleep parameter baseline : placebo &amp; pioglitazone ; placebo &amp; leuprolide/estrogen/progestin ; pioglitazone &amp; leuprolide/estrogen/progestin . Specific Aim 2 : test hypothesis sleep disturbance cause hormonal , metabolic cardiovascular alteration see woman PCOS . PCOS woman SDB match control woman SDB evaluate baseline follow 8 week CPAP treatment . The primary comparison baseline post-treatment parameter PCOS woman . The secondary comparison post-treatment change baseline PCOS control woman test hypothesis degree improvement SDB , magnitude change metabolic cardiovascular measure great PCOS control . Specific Aim 3 : test hypothesis normal young woman , experimental manipulation sleep recapitulate sleep disturbance characteristic woman PCOS result metabolic , hormonal , cardiovascular alteration typical metabolic syndrome . A group healthy young woman study twice use randomize cross-over design . In one study , rapid eye movement ( REM ) sleep fragment experimentally induced microarousals 3 consecutive night non-REM sleep left undisturbed . In , slow wave activity suppress without awaken subject REM sleep leave undisturbed . Each study precede 2 night baseline sleep . Results report Aim 3 since device drug test aim .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Progestins</mesh_term>
	<criteria>PCOS subject recruit Endocrinology Clinics University Chicago . All least 2 year postmenarche less 40 year age . A diagnosis PCOS require : presence oligo/amenorrhea ; hyperandrogenemia , define supranormal plasma free testosterone level ( &gt; 10 pg/ml ) ; hyperandrogenism , evidence infertility , hirsutism , acne , androgenetic alopecia ; exclusion nonclassic 21hydroxylase deficiency congenital adrenal hyperplasia , Cushing 's syndrome , hypothyroidism , significant elevation serum prolactin . Thus , subject meet National Institutes Health ( NIH ) consensus criterion PCOS . Control subject match , closely possible , age , ethnicity , body mass index ( BMI ) , body fat distribution [ assess single cut abdominal compute tomography ( CT ) scan dual energy xray absorptiometry ( DEXA ) scan ] . Normal lean ( BMI &lt; 25 kg/m2 ) woman 18 40 year age , good health , normal menstrual cycle , sleep complaint , history endocrine disorder . All study initiate early follicular phase ( day 24 ) . For least 2 month study , subject ( PCOS control ) must take steroid preparation ( include oral contraceptive ) , medication know alter insulin secretion and/or action , medication know influence sleep .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>polycystic ovary syndrome</keyword>
	<keyword>metabolic syndrome</keyword>
	<keyword>obstructive sleep apnea</keyword>
	<keyword>impaired glucose tolerance</keyword>
	<keyword>insulin resistance</keyword>
</DOC>